Metabolic control of regulatory T cell functional identity
Metabolic control of regulatory T cell functional identity
批准号:
10677731
负责人:
Greg M. Delgoffe
金额:
$60.25万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-05 至 2026-07-31
关键词:
AcetylationAffectAutoimmuneAutoimmune DiseasesAutoimmunityBacteriaBindingCD4 Positive T LymphocytesCTLA4 blockadeCell physiologyCellsCellular biologyChemosensitizationCouplingCuesDataDiseaseEnteralEnvironmentEpigenetic ProcessEquilibriumEventExposure toFOXP3 geneFunctional disorderGenesGeneticGlucoseGnotobioticHistonesHyperactivityImmune responseImmune systemImmunityImmunologicsImmunotherapyIn VitroInfectionInflammationInflammatoryIntestinesLactate TransporterLactic acidLactobacillusLinkMalignant NeoplasmsMeasurementMetabolicMetabolic ControlMetabolismModelingMusNormal tissue morphologyNutrientPathologyPathway interactionsPeripheralPlayPredispositionRegulatory T-LymphocyteRoleShapesSiteSmall IntestinesSupporting CellSystemT-Cell ProliferationT-LymphocyteTissuesTumor-DerivedWorkalpha ketoglutaratecancer celldemethylationdesigndysbiosiseffector T cellepigenomeglucose metabolismgut inflammationhistone modificationimmunomodulatory therapiesin vivoin vivo Modelmetabolic profilemicrobiotamouse modelnoveltooltranscription factortumortumor microenvironmentuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Treg cells are enriched within the tissues, one of their main sites of action and possess a number of
adaptations that allow them to thrive and maintain a stable lineage identity. One of these critical features is an
altered metabolic profile. We have explored how the metabolism of various tissue environments, especially
within tumors, stabilize regulatory T cell function. Tumors produce a local metabolic environment that is toxic to
conventional, effector T cells, but regulatory T cells thrive there, being highly proliferative and maintaining
stable function. Metabolic derangement of cancer cells and the potentiation of regulatory T cell function are
linked: we have recently shown that Treg cells are supported by tumor-derived metabolites, most notably lactic
acid. Treg cells eschew glucose metabolism, upregulating genes allowing them to withstand lactic acid-rich
conditions and utilize this metabolite to fuel their function. Foxp3-restricted deletion of the lactate transporter
monocarboxylate transporter 1 (MCT1, encoded by Slc16a1), hindered Treg function within tumors, resulting in
a more immunologically active environment. Importantly, Treg cell-targeting immunotherapies like CTLA-4
blockade drives Treg cells to utilize glucose rather than lactate. Notably, this Treg utilization of glucose vs.
lactate was not limited to tumors, but also found in the peripheral tissues of mice. While deletion of MCT1
resulted in no autoimmunity at the steady state, MCT1-deficient Treg cells were unable to sufficiently control
intestinal inflammation in a T cell transfer model. Even in isolation, high glucose concentrations can hinder
Treg cell function and stability, while lactate can protect against these differentiation events. Mechanistically,
lactate broadly supports Treg cell proliferation and function, but how alternative pathways like lactate
metabolism support and drive Treg cell identity remains unclear. Treg cells are not solely programmed by
Foxp3, but rather rely on an established epigenetic landscape that supports their function, both in where Foxp3
can bind but also other key transcription factors. It now is clear that metabolic intermediates play critical roles
in epigenetic remodeling, as histones can be either directly modified by metabolites (acetylation) or modified
through metabolic processes (demethylation requiring αKG). Recently, lactate itself has been shown to directly
modify histones, although the epigenetic consequences of histone lactylation remain incompletely described.
Our preliminary data suggest that Treg cells harbor elevated lactylation of histones in an MCT1-dependent
manner, and that Treg cells with increased lactylation harbor a more stable Treg cell signature. Here we will
address the hypothesis that metabolites, most notably lactate, enriched in the tissues drive regulatory T cell
functional identity, using in vivo systems in which Treg cells are either unfavorably stabilized (cancer) or
struggle to control immunity (intestinal inflammation), coupling novel mouse models with functional and
epigenetic analyses feasible to profile these rare cells. This work will transform our understanding of how
context/tissue-specific cues like metabolites can help shape Treg cell function and fate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dissecting the role of hypoxia in T cell differentiation in cancer
-
批准号:10578000
-
项目类别:
-
资助金额:$61.45万
-
财政年份:2023
-
负责人:Greg M. Delgoffe
-
依托单位:
Metabolic control of regulatory T cell functional identity
-
批准号:10510537
-
项目类别:
-
资助金额:$60.25万
-
财政年份:2022
-
负责人:Greg M. Delgoffe
-
依托单位:
Uncovering the metabolic underpinnings of T cell exhaustion
-
批准号:10707255
-
项目类别:
-
资助金额:$64.04万
-
财政年份:2022
-
负责人:Greg M. Delgoffe
-
依托单位:
Uncovering the metabolic underpinnings of T cell exhaustion
-
批准号:10593593
-
项目类别:
-
资助金额:$63.36万
-
财政年份:2022
-
负责人:Greg M. Delgoffe
-
依托单位:
Exploring and exploiting metabolic plasticity in regulatory T cells
-
批准号:9348845
-
项目类别:
-
资助金额:$230.11万
-
财政年份:2017
-
负责人:Greg M. Delgoffe
-
依托单位:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
-
批准号:8255282
-
项目类别:
-
资助金额:$4.92万
-
财政年份:2012
-
负责人:Greg M. Delgoffe
-
依托单位:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
-
批准号:8610875
-
项目类别:
-
资助金额:$1.97万
-
财政年份:2012
-
负责人:Greg M. Delgoffe
-
依托单位:
Elucidating the regulation of interleukin-35, a regulatory cytokine, in T cells
-
批准号:8432601
-
项目类别:
-
资助金额:$5.22万
-
财政年份:2012
-
负责人:Greg M. Delgoffe
-
依托单位:
Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
-
批准号:10331957
-
项目类别:
-
资助金额:$31.71万
-
财政年份:2004
-
负责人:Greg M. Delgoffe
-
依托单位:
Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)
-
批准号:10704505
-
项目类别:
-
资助金额:$31.68万
-
财政年份:2004
-
负责人:Greg M. Delgoffe
-
依托单位:
海外基金